Wells Fargo’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-28,118
| Closed | -$64.1K | – | 7127 |
|
|
2024
Q2 | $64.1K | Sell |
28,118
-2,947
| -9% | -$11.3K | ﹤0.01% | 5189 |
|
|
2024
Q1 | $134K | Buy |
31,065
+8,507
| +38% | +$29.6K | ﹤0.01% | 4721 |
|
|
2023
Q4 | $68.8K | Buy |
22,558
+1,317
| +6% | +$2.48K | ﹤0.01% | 5132 |
|
|
2023
Q3 | $30.6K | Sell |
21,241
-9,392
| -31% | -$18.2K | ﹤0.01% | 5426 |
|
|
2023
Q2 | $76.3K | Buy |
30,633
+2,794
| +10% | +$7.63K | ﹤0.01% | 5201 |
|
|
2023
Q1 | $74.6K | Buy |
27,839
+2,347
| +9% | +$11.3K | ﹤0.01% | 4962 |
|
|
2022
Q4 | $138K | Sell |
25,492
-28,869
| -53% | -$242K | ﹤0.01% | 4368 |
|
|
2022
Q3 | $680K | Buy |
54,361
+22,606
| +71% | +$258K | ﹤0.01% | 3493 |
|
|
2022
Q2 | $157K | Sell |
31,755
-13,383
| -30% | -$74.1K | ﹤0.01% | 4410 |
|
|
2022
Q1 | $343K | Sell |
45,138
-12,349
| -21% | -$117K | ﹤0.01% | 4666 |
|
|
2021
Q4 | $587K | Sell |
57,487
-48,918
| -46% | -$623K | ﹤0.01% | 4531 |
|
|
2021
Q3 | $1.43M | Buy |
106,405
+9,606
| +10% | +$157K | ﹤0.01% | 3939 |
|
|
2021
Q2 | $2.12M | Buy |
96,799
+18,102
| +23% | +$402K | ﹤0.01% | 3642 |
|
|
2021
Q1 | $1.89M | Buy |
78,697
+36,544
| +87% | +$849K | ﹤0.01% | 3749 |
|
|
2020
Q4 | $758K | Buy |
42,153
+11,952
| +40% | +$179K | ﹤0.01% | 4223 |
|
|
2020
Q3 | $349K | Buy |
30,201
+2,554
| +9% | +$42.2K | ﹤0.01% | 4617 |
|
|
2020
Q2 | $671K | Buy |
27,647
+8,081
| +41% | +$134K | ﹤0.01% | 4116 |
|
|
2020
Q1 | $216K | Buy |
19,566
+549
| +3% | +$10.3K | ﹤0.01% | 4635 |
|
|
2019
Q4 | $502K | Sell |
19,017
-956
| -5% | -$22.4K | ﹤0.01% | 4364 |
|
|
2019
Q3 | $455K | Buy |
19,973
+6,337
| +46% | +$200K | ﹤0.01% | 4443 |
|
|
2019
Q2 | $418K | Sell |
13,636
-1,489
| -10% | -$31.3K | ﹤0.01% | 4507 |
|
|
2019
Q1 | $251K | Sell |
15,125
-11
| -0.1% | -$209 | ﹤0.01% | 4706 |
|
|
2018
Q4 | $290K | Buy |
15,136
+4,827
| +47% | +$181K | ﹤0.01% | 4694 |
|
|
2018
Q3 | $539K | Buy |
10,309
+675
| +7% | +$36.8K | ﹤0.01% | 4386 |
|
|
2018
Q2 | $419K | Buy |
9,634
+4,080
| +73% | +$175K | ﹤0.01% | 4593 |
|
|
2018
Q1 | $206K | Buy |
5,554
+899
| +19% | +$24K | ﹤0.01% | 4973 |
|
|
2017
Q4 | $92K | Buy |
4,655
+4,107
| +749% | +$88.3K | ﹤0.01% | 5351 |
|
|
2017
Q3 | $14K | Buy |
+548
| New | +$10.1K | ﹤0.01% | 5800 |
|
Wells Fargo's GTHX Position: Q3 2024 in Review
Wells Fargo sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 28,118 shares — an estimated $64.1K sold.
Wells Fargo first reported a position in GTHX in Q3 2017 and held it in 28 quarters. The position peaked at $2.12M in Q2 2021. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Wells Fargo reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Wells Fargo sold 28,118 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $64.1K.
- Wells Fargo first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2017 and held it in 28 quarters.
- Wells Fargo's G1 Therapeutics, Inc. Common Stock position peaked at $2.12M in Q2 2021.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Wells Fargo's 13F filing for Q3 2024, filed 13 Nov 2024.